Clinical application of capecitabine as adjuvant chemotherapy of gastric cancer in aged patients
10.3760/cma.j.issn.1008-6315.2009.07.031
- VernacularTitle:卡培他滨单药在老年胃癌辅助治疗中的临床应用
- Author:
Xia YUAN
- Publication Type:Journal Article
- Keywords:
Gastric cancer;
Capecitabine;
Aged patients;
adjuvant chemotherapy
- From:
Clinical Medicine of China
2009;25(7):750-752
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the short-term efficacy and adverse effects of capecitabine as adjuvant chemotherapy of gastric cancer after resection in aged patients. Methods Sixty aged patients with gastric cancer (Ⅱ-Ⅲstage) after resection were randomized to two groups: the high dose group,in which 30 patients were treated least 6 therapeutic cycles (3 weeks for 1 cycle). Efficacy and adverse effects were assessed after 2 cycles. Results Two years' survival was 80% (24/30) in the high dose group and 77% (23/30) in the low dose group (χ2=0.54,P=0.45). The recurrence-free survival time was 19.2 months and 19.0 months respectively (χ2=0.82,P=0.36). Patients in the high dose group experienced more significant nausea/vomiting (Ⅰ-Ⅱ grade) than patients in the low dose group (χ2 = 9.82,P=0.02). However,there was no significant difference on grade Ⅲ-Ⅳ nausea/vomi-ting between the 2 groups(χ2=0.34,P=0.71). The incidence of grade Ⅰ-Ⅳ mucositis,hyperbilirubinemia and hand-foot syndrome (HFS) in the high dose group were higher than in the low dose group( P=0. 04,0. 02 and 0.04,respectively). There was no difference on weakness,lack of appetite and neutropenia between the two groups. in aged patients with similar efficacy and better tolerance of adverse effects compared to capeeitabine [2500 mg/
